We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Decrement in Hemoglobin Levels Is Indicative of Colorectal Cancer

By LabMedica International staff writers
Posted on 19 Aug 2010
Long-term variation in blood hemoglobin (Hb) levels could detect subtle gastrointestinal bleeding in the early development of colorectal cancer (CRC). More...


Anemia, a common blood disorder, is characterized by low Hb levels, and has long been associated with those suffering from CRC. A sharp decrease in Hb levels was thought to be a symptom of colon cancer.

In a recent study carried out at the School of Public Health, Tel Aviv University (Tel Aviv, Israel), a total of 1,074 CRC cases aged 45–75 years that had been diagnosed with CRC and had normal Hb levels were frequency matched for age and sex with cancer-free individuals at a ratio of 10 controls per case. In this retrospective study, the scientists looked at data from each participant's blood tests over a ten-year period, retrieved from a computerized database.

The scientists have discovered that it is the continuous long-term decline that may announce the onset of cancer. Though hemoglobin levels may vary in every human being as a result of aging, a distinct trend was discovered among study participants who had been diagnosed with colorectal cancer during the study period. Approximately four years prior to their diagnoses, their blood tests began to show a continuous decline in Hb levels. A declining trend of more than 0.28 g/dL every six months over a four-year period was observed and it may serve as a warning of illness on the horizon. CRC patients were characterized by an on-going, long-term, logarithmic decrement in Hb levels. Such small changes within the normal Hb range could be missed by health providers, but automatically detected by computerized alert algorithms. Participants of the study with colorectal cancer experienced a sharp decline in Hb levels, but because the declines did not put them outside the normal range, no red flags were raised.

Inbal Goldshtein, a graduate student and lead author of the study said, "In practice, a doctor will look at the final results and see if the hemoglobin levels are within a normal range, but this is not accurate enough. It is important to look at the continuing trend of each individual. If a person experiences a consistent decline relative to his own average level, it may be cause for concern." The study was published in the July 2010 issue of the European Journal of Cancer Prevention.

The benefit of this screening process is that can be part of an average physical. Current testing for colorectal cancer is often expensive and unpleasant and there is also a very low compliance rate among patients. The next step is to create an algorithm, which will automatically detect suspicious declines in Hb levels, advising physicians to send their patients for further testing. More than 50,000 people in the U.S.A. will die from colon cancer in 2010, but better screening could significantly reduce those numbers.

Related Links:

Tel Aviv University




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.